Mechanisms of acquired resistance to targeted cancer therapies.
about
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?Antibody-drug conjugates as novel anti-cancer chemotherapeuticsTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentBufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum StressCombinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSafety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trialSynergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell linesHost defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis.Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugsBioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerCancer heterogeneity: implications for targeted therapeutics.Potential therapeutic targets for oral cancer: ADM, TP53, EGFR, LYN, CTLA4, SKIL, CTGF, CD70.Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsNetwork pharmacology-based virtual screening of natural products from Clerodendrum species for identification of novel anti-cancer therapeutics.Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib.Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Improving cancer therapy by combining cell biological, physical, and molecular targeting strategies.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinomaERRα mediates metabolic adaptations driving lapatinib resistance in breast cancerOpportunities and challenges in combination gene cancer therapy.Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cellsTargeted therapies in breast cancer: New challenges to fight against resistance.Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles.Resistance acquisition to MDM2 inhibitors.Progress and perspectives of biomarker discovery in Chinese medicine research.Translational hematology.Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.Photochemical activation of drugs for the treatment of therapy-resistant cancers.STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug ResistanceDesign, synthesis and biological evaluation of regioisomers of 666-15 as inhibitors of CREB-mediated gene transcription.Comparison of patient-derived high and low phosphatidylserine-exposing colorectal carcinoma cells in their interaction with anti-cancer peptides.Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance.TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.
P2860
Q26782649-991C5931-09E0-4066-887C-1423362B93E7Q26800175-D52F2EA1-6BF2-4C84-A767-C5623EA6991EQ28076462-9D8866D4-54B7-415E-B6AD-FD939492ADECQ28548246-68B7FCA1-66EF-494E-AE73-E30D2E347BD6Q30418057-50AC69EE-5E45-476C-95F8-4ECA8B0C3C80Q33431267-A30863DC-5232-4FFB-9683-315254B0090AQ33822560-9C051098-6188-4F19-8FAE-99447E6004DAQ34101011-CF5ADAF5-9E5D-4A94-B6C0-1A937F614011Q34123603-37D87585-69DD-43EA-B531-DAC3C94A2885Q34295621-D335FB26-90A4-414C-9776-882BDD49BFBAQ34321565-99677CBD-5F69-48FE-82E3-7BADDC11E5E1Q34663230-DC31CC9F-B37A-4FF8-8F04-7EB352462A1AQ35412202-22A98B87-7F84-4274-8EF7-707239E11CB9Q35497448-448659B5-56AF-4638-98DF-18FAA72B163AQ35858617-A668B441-97E2-4FB2-ADFB-15BCB4231A3BQ36245161-D89D640B-BC71-4AE8-976A-E8ECEF3E8222Q36290275-B3B644EB-9DFC-46AA-9100-470F2A8C3079Q36554387-B738181B-FAB0-4328-A2BE-89803D8A268FQ36557155-0E9943C9-6F35-4F4B-957B-6BB008FAEFB8Q36557486-620CDEF7-5114-46DF-8459-67C1FA1AFE89Q36563213-972F7C69-8D4D-4423-840A-369452FAD1CDQ37049104-C76D5104-CFFA-4EC5-89E7-D1963EA4476DQ37096669-6A2118B1-FBA0-4ECC-87FF-972A8941BACDQ37118663-1AED51C5-A00C-4261-B78C-36C14F00E6B3Q37317194-97304ADC-A8D2-492F-B748-45D281FAACC4Q37743048-67A85A03-7B53-49E1-A5D5-AC01C902EE28Q38093187-EDF40BEF-26AC-4CFD-9F2F-80F1ECD6B225Q38238600-320AA764-E352-4565-9046-70B2AB66899DQ38245559-E85A4545-5635-4D7A-B58A-44D4FA5AFB8FQ38247744-92437A01-CF77-4982-AB35-35D8251573F5Q38261107-5833BDEA-485A-4751-ABF9-68255C189382Q38319572-57FFD3C6-572B-4724-88AC-AB129B1E6E59Q38324456-990EDB28-82F7-4C8A-A4F2-6228644D12B6Q38409528-06CAD5C0-70A6-4FF4-91DE-277693E9FECDQ38536624-C95D8296-F439-4399-B777-9794EC74676EQ38722053-9A7999BA-16A1-41A9-9A4B-CE9EA483BEAFQ38722377-5B4B1738-D4C5-4020-98DC-705AF097399BQ38764654-AADBF57F-F0EC-408E-A485-2A7AB3F2A3EAQ38821729-2FA3C587-CDFD-4D1B-B091-9ED97F50F2D4Q38839046-19B9C943-4F44-4461-8E8A-47E96DEF26D8
P2860
Mechanisms of acquired resistance to targeted cancer therapies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mechanisms of acquired resistance to targeted cancer therapies.
@en
type
label
Mechanisms of acquired resistance to targeted cancer therapies.
@en
prefLabel
Mechanisms of acquired resistance to targeted cancer therapies.
@en
P2860
P356
P1433
P1476
Mechanisms of acquired resistance to targeted cancer therapies
@en
P2093
Jeff Settleman
Timothy R Wilson
P2860
P304
P356
10.2217/FON.12.86
P407
P577
2012-08-01T00:00:00Z